Our Work in Immunology
Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape. In Immunology SGI focuses on three key areas: Rheumatology, Dermatology and Gastroenterology, aiming to provide insight and answer critical questions. With many drugs approved for multiple auto-immune conditions, our reports enable comparison across disease states and specialist types into the different ways drugs are adopted and utilized. Tracking launches in so many conditions, we have historical proxies for pipeline assets coming to market, highlight what ‘good’ and ‘bad’ looks like in terms of market entry. The focus on dynamic segments in each market including: launch, biologic switching, biologic new starts and re-starts, we have all the active segments that drive brand health covered.